利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

282 records (took 0.036 seconds)

    TISSUE CULTURE SYSTEM FOR PRODUCTION OF HEPATITIS C VIRUS
    21.
    发明申请
    TISSUE CULTURE SYSTEM FOR PRODUCTION OF HEPATITIS C VIRUS 有权
    用于生产乙型肝炎病毒的组织培养系统

    公开(公告)号：US20100227311A1

    公开(公告)日：2010-09-09

    申请号：US12310309

    申请日：2007-08-22

    Applicant: Jang Han ,  Qui-Lim Choo ,  Michael Houghton ,  Taewoo Kwon ,  Hyun Chul Song ,  Yifei Zhu

    Inventor： Jang Han ,  Qui-Lim Choo ,  Michael Houghton ,  Taewoo Kwon ,  Hyun Chul Song ,  Yifei Zhu

    IPC: C12Q1/70 ,  C12N15/74 ,  C12N5/10 ,  C12N7/00 ,  G01N33/567

    CPC classification number: C12N7/00 ,  A61K2039/525 ,  C07K14/005 ,  C07K2319/61 ,  C12N2760/16022 ,  C12N2770/24243 ,  G01N2333/186 ,  G01N2500/10

    Abstract: A tissue culture system for production of infectious hepatitis C virus is described. In particular, the invention provides recombinant monocistronic and bicistronic genomic constructs for production of virus, including constructs for production of wild-type HCV type 2a strain JFH1 and constructs for production of chimeric viruses comprising HCV proteins from strain JFH1 and a second HCV isolate. Constructs of the invention also include a reporter gene to facilitate measurement of RNA replication and viral infectivity in cultures. The cell culture system may also include various factors that improve viral replication or infectivity. In addition, a neutralization assay using HCV grown in cell culture is described.

    Abstract translation: 描述了用于生产感染性丙型肝炎病毒的组织培养系统。 特别地，本发明提供了用于产生病毒的重组单顺反子和双顺反子基因组构建体，包括用于产生野生型HCV 2a型菌株JFH1的构建体和用于产生包含来自菌株JFH1的HCV蛋白质和第二HCV分离物的嵌合病毒的构建体。 本发明的构建体还包括有利于测量培养物中RNA复制和病毒感染性的报告基因。 细胞培养系统还可以包括改善病毒复制或感染性的各种因素。 此外，描述了使用在细胞培养物中生长的HCV的中和测定。

    Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
    22.
    发明授权
    Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof 失效
    含有新靶向和/或融合肽的脂质体，含有它们的制剂及其治疗用途

    公开(公告)号：US07741431B2

    公开(公告)日：2010-06-22

    申请号：US11339404

    申请日：2006-01-25

    Applicant: Nahum Allon ,  Carolyn Chambers ,  Ashima Saxena ,  Bhupendra P. Doctor

    Inventor： Nahum Allon ,  Carolyn Chambers ,  Ashima Saxena ,  Bhupendra P. Doctor

    IPC: A61K38/00 ,  A61K38/04 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

    CPC classification number: A61K9/1272 ,  C07K14/005 ,  C07K14/57536 ,  C12N2760/16022

    Abstract: A novel targeting peptide from the C-terminal of endothelin and/or a novel fusogenic peptide from hemagglutinin are optionally conjugated to the carboxy group of 1,2-dioleoyl-sn-glycero-3-succinate and incorporated into liposomes for therapeutic treatment. The novel targeting peptide directs liposomes to lung cells, and, therefore, is useful for delivering liposomes encapsulating cholinesterase genes, particularly, the human serum butyryl cholinesterase (Hu BChE) gene, as a treatment against nerve agents. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims. 37 CFR §1.72(b).

    Abstract translation: 任选地，将来自血管凝血酶的C端的新型靶向肽和/或来自血凝素的新的融合肽缀合到1,2-二油酰-sn-甘油基-3-琥珀酸酯的羧基上并且并入脂质体中进行治疗。 新型靶向肽将脂质体引导至肺细胞，因此可用于递送包封胆碱酯酶基因的脂质体，特别是人血清丁酰胆碱酯酶（Hu BChE）基因作为神经药物的治疗。 要强调的是，该摘要被提供以符合要求抽象的规则，这将允许搜索者或其他读者快速地确定技术公开的主题。 提交它的理解是，它不会用于解释或限制所附权利要求的范围或含义。 37 CFR§1.72（b）。

    PRODUCTION AND IN VIVO ASSEMBLY OF SOLUBLE RECOMBINANT ICOSAHEDRAL VIRUS-LIKE PARTICLES
    23.
    发明申请
    PRODUCTION AND IN VIVO ASSEMBLY OF SOLUBLE RECOMBINANT ICOSAHEDRAL VIRUS-LIKE PARTICLES 审中-公开
    可溶性重组体ICOSAHEDRAL病毒颗粒的生产和生殖器

    公开(公告)号：US20090093019A1

    公开(公告)日：2009-04-09

    申请号：US12110257

    申请日：2008-04-25

    Applicant: Jamie P. Phelps ,  Lada Rasochova

    Inventor： Jamie P. Phelps ,  Lada Rasochova

    IPC: C12P21/04

    CPC classification number: C12N7/00 ,  A61K2039/5256 ,  A61K2039/5258 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/16022 ,  C12N2770/14022 ,  C12N2770/14023 ,  C12N2795/10243

    Abstract: The present invention provides an improved method for the in vivo production of soluble assembled virus-like particles (“VLPs”) in bacterial cells of Pseudomonad origin. The Pseudomonad cells support assembly of VLPs from icosahedral viral capsid proteins (“CPs”) in vivo, and allow the inclusion of larger recombinant peptides as monomers or concatamers in the VLP. The invention specifically provides an improved method for the in vivo production of soluble assembled Cowpea Chlorotic Mottle Virus (“CCMV”) VLPs by introducing modifications into the CCMV CP that result in high yield production of soluble CP fusions in a Pseudomonas fluorescens bacterial system. These soluble VLPs can subsequently be purified and used as vaccines.

    Abstract translation: 本发明提供了在假单胞菌来源的细菌细胞体内生产可溶性组装病毒样颗粒（“VLP”）的改进方法。 假单胞菌细胞在体内支持来自二十面体病毒衣壳蛋白（“CP”）的VLP的组装，并且允许在VLP中包含较大的重组肽作为单体或连接体。 本发明具体提供了一种用于体内生产可溶性组装Cow豆褪绿斑马鱼病毒（“CCMV”）VLP的改进方法，该方法通过在CCMV CP中引入修饰，导致荧光假单胞菌细菌系统中可溶性CP融合物的高产量产生。 随后可将这些可溶性VLP纯化并用作疫苗。

    Compositions for lipid matrix-assisted chemical ligation
    25.
    发明授权
    Compositions for lipid matrix-assisted chemical ligation 失效
    用于脂质基质辅助化学连接的组合物

    公开(公告)号：US07482425B2

    公开(公告)日：2009-01-27

    申请号：US10207330

    申请日：2002-07-30

    Applicant: Gerd. G. Kochendoerfer ,  Christie L. Hunter ,  Stephen B. H. Kent ,  Paolo Botti

    Inventor： Gerd. G. Kochendoerfer ,  Christie L. Hunter ,  Stephen B. H. Kent ,  Paolo Botti

    IPC: A61K38/00

    CPC classification number: C07K14/005 ,  C07K1/023 ,  C07K1/026 ,  C07K1/04 ,  C07K1/042 ,  C07K14/215 ,  C07K14/245 ,  C07K14/36 ,  C07K14/43522 ,  C07K14/5421 ,  C07K14/705 ,  C07K2319/00 ,  C12N2740/16322 ,  C12N2760/16022

    Abstract: The present invention relates to methods and compositions for lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides that are incorporated in a lipid matrix. The invention is exemplified in production of a prefolded membrane polypeptide embedded within a lipid matrix via stepwise chemoselective chemical ligation of unprotected peptide segments, where at least one peptide segment is embedded in a lipid matrix. Any chemoselective reaction chemistry amenable for ligation of unprotected peptide segments can be employed. Suitable lipid matrices include liposomes, micelles, cell membrane patches and optically isotropic cubic lipidic phase matrices. Prefolded synthetic and semi-synthetic membrane polypeptides synthesized according to the methods and compositions of the invention also permit site-specific incorporation of one or more detectable moieties, such as a chromophore, which can be conveniently introduced during synthesis. The methods and compositions of the invention have multiple uses. For example, they can be used to assay ligand binding to membrane polypeptides and domains comprising a receptor, and thus are extremely useful for structure/function studies, drug screening/selection/design, and diagnostics and the like, including high-throughput applications. The methods and compositions of the invention are particularly suited for FRET analyses of previously inaccessible membrane polypeptides.

    Abstract translation: 本发明涉及掺入脂质基质中的脂质基质辅助化学连接和膜多肽的合成的方法和组合物。 本发明通过逐步化学选择性化学连接未受保护的肽段（其中至少一个肽片段嵌入脂质基质）生产嵌入脂质基质内的预折叠膜多肽。 可以使用适用于未保护肽段连接的任何化学选择性反应化学物质。 合适的脂质基质包括脂质体，胶束，细胞膜片和光学各向同性立体脂质相基质。 根据本发明的方法和组合物合成的预先折叠的合成和半合成膜多肽还允许位点特异性引入一个或多个可检测部分，例如发色团，其可以在合成期间方便地引入。 本发明的方法和组合物具有多种用途。 例如，它们可用于测定配体结合膜多肽和包含受体的结构域，因此对于结构/功能研究，药物筛选/选择/设计和诊断等（包括高通量应用）非常有用。 本发明的方法和组合物特别适用于以前不可接近的膜多肽的FRET分析。

    Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
    26.
    发明授权
    Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo 失效
    融合蛋白构建体和体内诱导HIV特异性血清IgG和分泌型IgA抗体的方法

    公开(公告)号：US07262270B2

    公开(公告)日：2007-08-28

    申请号：US10655667

    申请日：2003-09-05

    Applicant: Winfried Weissenhorn ,  David Prashker, legal representative ,  Nicholas Mantis ,  Marian R. Neutra ,  Pamela Kozlowski

    Inventor： Don Wiley, deceased

    IPC: A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  C07K1/00

    CPC classification number: C07K14/005 ,  A61K2039/54 ,  A61K2039/542 ,  A61K2039/545 ,  C07K2319/00 ,  C12N2740/16122 ,  C12N2760/16022 ,  Y10S530/826

    Abstract: The present invention provides a fusion protein construct (gp41HA) consisting of the ectodomain of the HIV-1IIIB envelope glycoprotein gp41 fused to a fragment of the influenza virus HA2 hemagglutinin protein. Immunization in-vivo via an intraperitoneal prime followed by intranasal or intragastric boosts with gp41HA induces high concentrations of serum IgG antibodies and fecal IgA antibodies that reacted with gp41 in HIV-1IIIB viral lysate and are cross-reactive with gp41 in HIV-1MN lysate. Followup analyses by indirect immunofluorescence showed that both serum IgG and fecal IgA recognized human peripheral blood mononuclear cells infected with either syncytium-inducing (SI) or non-syncytium-inducing (NSI) North American HIV-1 field isolates, but not uninfected cells.

    Abstract translation: 本发明提供了融合蛋白质构建体（gp41HA），其由与流感病毒HA2血凝素蛋白片段融合的HIV-1 IIIB包膜糖蛋白gp41的胞外域组成。 通过腹膜内注射进行体内免疫，随后用gp41HA进行鼻内或胃内加压，诱导高浓度的血清IgG抗体和与HIV-1 IIIB III病毒裂解物中的gp41反应的血清IgG抗体和粪便IgA抗体，并且是交叉反应性 在HIV-1 MN溶解产物中具有gp41。 通过间接免疫荧光进行的随访分析显示，血清IgG和粪便IgA均识别出感染合胞体诱导（SI）或非合胞体诱导（NSI）北美HIV-1场分离株但不是未感染细胞的人外周血单核细胞。

    Peptide composition and method for delivering substances into the cytosol of cells
    29.
    发明授权
    Peptide composition and method for delivering substances into the cytosol of cells 失效
    用于将物质输送到细胞胞质溶胶中的肽组合物和方法

    公开(公告)号：US07084248B2

    公开(公告)日：2006-08-01

    申请号：US10945153

    申请日：2004-09-20

    Applicant: James Edward Summerton

    Inventor： James Edward Summerton

    IPC: A61K38/06 ,  A61K38/00

    CPC classification number: A61K9/0019 ,  A61K38/00 ,  A61K47/26 ,  A61K47/64 ,  C07K14/005 ,  C07K2319/10 ,  C12N15/87 ,  C12N2760/16022 ,  C12N2810/6072

    Abstract: Weak-base amphiphilic delivery peptide compositions are described for use in delivering large polar substances (cargo) into the cytosol of animal cells via an indirect endocytosis-mediated delivery process. The delivery peptides, which are predominantly non-ionic at neutral pH, bind but do not permeabilize cell membranes. After endocytosis of both delivery peptides and cargo, acidification of the endosome converts the delivery peptides to their polycationic form, whereupon they permeabilize the endosomal membrane and allow co-endocytosed cargo to pass from the endosome to the cytosol of the cell.

    Abstract translation: 描述了弱碱性两亲递送肽组合物，用于通过间接内吞作用介导的递送过程将大极性物质（货物）递送到动物细胞的细胞溶质中。 在中性pH下主要是非离子的递送肽结合但不透化细胞膜。 在递送肽和货物的内吞之后，内体的酸化将递送肽转化为它们的阳离子形式，于是它们渗透内体膜并允许共胞吞噬的货物从内体进入细胞的胞质溶胶。

Patent Agency Ranking